A5095942260- Brain Metastases and Treatment
- Lung Cancer Treatments and Mutations
- Pregnancy and Medication Impact
- Cancer Genomics and Diagnostics
- Pulmonary Hypertension Research and Treatments
- Dialysis and Renal Disease Management
- HER2/EGFR in Cancer Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Research Studies
- Renal Diseases and Glomerulopathies
AstraZeneca (United Kingdom)
2024
Leptomeningeal metastases (LMs) exhibit a high incidence in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) post-treatment first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). This investigation evaluates the efficacy, safety, and pharmacokinetics of 80 mg once daily osimertinib LMs resistant to prior TKIs.
The endothelin A receptor antagonist zibotentan, combined with the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin, is being investigated for treatment of chronic kidney disease high proteinuria. To allow women childbearing potential access to this treatment, highly effective contraception required and drug interactions compromising reliability must be avoided. This study risk pharmacokinetic (PK) interaction between zibotentan contraceptives ethinyl estradiol levonorgestrel....
8582 Background: Leptomeningeal metastases (LM) present with a high incidence in EGFR-mutated NSCLC following treatment first- or second-generation EGFR TKIs. Osimertinib has demonstrated significant clinical efficacy LM at double dose (160mg), attributed to its superior blood-brain barrier penetration. This study aims delineate the efficacy, safety, and pharmacokinetic profile of 80mg osimertinib for patients exhibiting resistance earlier-generation Methods: The BLOSSOM trial is Phase II,...